Index1
1This relates to the hard copy.
A
accountability and management, 68–81
see also finance
acronyms and abbreviations list, 178–180
Activated Prothrombin Complex Concentrate, 39
administered finances, 87–89
special accounts, 85
administrative tribunal decisions, 73
advertising and market research, 164
age demographic of staff, 78
agency resource statements, 169–170
anaemia, 10, 55–57, 59
angioedema, 43
annual performance statement, 18–65
annual reports, 33, 43, 44
NBA, 13, 168; list of requirements, 171–177
Anti-Rh(D), 39
apheresis, 29, 35, 159
assets and asset management, 87, 90
administered items, 89
Audit Committee, 19, 69, 70, 71, 157
Australian Bleeding Disorders Registry (ABDR), 44, 46–47, 69
MyABDR portal, 47, 49
Australian Commission on Safety and Quality in Health Care (ACSQHC), 10, 59
Australian Haemophilia Centre Directors' Organisation (AHCDO), 8
Australian Information Commissioner, 73
Australian National Audit Office (Auditor-General, ANAO), 69, 73
Australian Public Service Commission Employee Census, 75, 80
Australian Red Cross Blood Service (Blood Service), 34–36
NMF (Blood and Blood Products) Special Account, 84–85
Review of Risk Management in the Blood Sector, 45
see also fresh blood
awards and recognition, 13, 48, 49
B
balance sheet, 87
Baxalta Australia Pty Ltd, 25, 40, 160, 161, 162
immunoglobulins (IVIg), 25, 38
Bayer Australia Limited, 25, 40, 161
Bio-Rad Laboratories Pty Ltd, 26, 40
bleeding, 10
see also haemophilia and bleeding disorders
blood cells, see red blood cells
Blood Service, see Australian Red Cross Blood Service
BloodMove Platelets project, 53
BloodNet, 22, 43, 48, 69
BloodNet User Reference Group, 48
BloodSafe eLearning Australia, 55, 59
BloodSTAR, 41, 48, 69
Board, 12–14, 71, 154–157
budget, see finance
C
C1 Esterase Inhibitor Concentrate, 43
capability reviews, 73
classification of staff, 77, 78–79
rationalisation of levels, 80
clinical demand, 21, 27–33
clinical practice guidelines, see Patient Blood Management (PBM) Guidelines
Clinical Transfusion Practice course, 59
clotting factors, see Factor VIIa; Factor VIII; Factor IX
Comcare, reportable incidents lodged with, 81
Commonwealth Ombudsman, 73
communication and promotion, 57–58
see also information communication technology
competitive tendering and contracting, 91
conferences and sector events, 46, 55, 57, 60
Rural Medicine Australia, 58
Victorian Wastage Summit, 61
consultants, 92
contracts, see purchasing
Corporate Plan, 14, 19, 70
Council of Australian Governments (COAG) Health Council, 3, 45, 87
Criteria for the clinical use of intravenous immunoglobulin in Australia (Criteria), 41, 42
critical bleeding/massive transfusion PBM Module 1, 10, 69
see also haemophilia and bleeding disorders
Critical Care Patient Blood Management Guideline Module, 59
CSL Behring (Australia) Pty Ltd, 25, 160, 161, 162, 163
Fractionation Agreement, 29, 30, 36–37
imports, 38, 40, 162, 163
Customer Service Charter, 73
D
data developments, 43–44
see also information communication technology
Deed of Agreement, Red Cross, 34–36, 45
demand, 21, 27–33
diagnostic reagent products, 26, 40
disability reporting, 168
discards, see wastage
donor management, Blood Service, 35, 36
E
ecologically sustainable development, 165–168
education and training, 59
staff, 74, 81
employees, 4, 74, 75–81
enterprise agreement, 78–79
environmental performance, 165–168
exempt contracts, 91
expenditure, see finance
external scrutiny, 73
F
Factor VIIa, 26, 31–32, 160
Factor VIII, 25, 30–31
clinical practice guidelines, 54
inhibitor bypass agent (FEIBA), 31, 32, 160
supply contracts, 30, 39, 160–161
Factor IX, 31
clinical practice guidelines, 54
supply contracts, 30, 161
Fibrinogen Concentrate, 39, 160
finance, 84–151, 169–170
Blood Service, 35, 84–85
grant programs, 64, 168
see also purchasing
financial assets, 87
financial statements, 94–151
audit report, 86
fractionation, see plasma and recombinant products
fraud control, 74
freedom of information, 168
fresh blood, 24, 27–29, 34–36, 44, 48
components supplied under contract, 159
see also Australian Red Cross Blood Service; patient blood management; platelets; red blood cells
full-time staff, 77
functions and role, 2, 12, 84
G
gender of staff, 77
General Manager, 3, 68, 69
review of year, 8–11
governance, 68–70
blood sector data and information, 44
immunoglobulin arrangements, 41–42, 64, 69
grant programs, 64, 168
Grifols Australia, 26, 38, 40, 162–163
H
haematology, 33, 40, 41, 42
haemophilia and bleeding disorders, 44, 46–47
MyABDR portal, 47, 49
national guidelines, 8, 54
see also Factor VIIa; Factor VIII; Factor IX
haemovigilance, 43–44
health provider Charter, 10
hereditary angioedema, 43
horizon scanning, 50–51
human resources, 4, 74, 75–81
I
immunoglobulins (IVIg), 30, 33, 162–163
CSL Behring Ltd supplies, 30, 36–37, 162, 163
governance arrangements, 41–42, 64, 69
imported supplies, 9, 25–26, 33, 38
immunology, 33, 41, 42
income, see finance
Indigenous employees, 77
information communication technology (ICT), 46–49, 68
BloodNet, 22, 43, 48, 69
BloodSafe eLearning Australia, 55, 59
BloodSTAR, 41, 48, 69
Information Framework Agreements, 44
Information Publication Scheme statement, 168
internal audit, 69, 70
international horizon scanning, 50–51
inventory management, 43
Blood Service, 35, 36
BloodNet, 22, 43, 48, 69
CSL Behring Ltd, 36–37, 38, 40
imported intravenous immunoglobulin, 38
imported plasma and recombinant blood products, 40
platelets, 35, 53
iron deficiency anaemia, 10, 55–57, 59
J
Johnson & Johnson Medical Pty Ltd, 26, 40
judicial decisions, 73
Jurisdictional Blood Committee (JBC), 43
Strategic Plan, 14, 70
K
key performance indicators,
see performance indicators
L
legal actions, 73
legislation, 3, 12, 19, 45, 74, 84
liabilities, see assets
M
management and accountability, 68–81
see also finance
Management Committee, 68
market research and advertising, 164
Medical Services Advisory Committee, 43
Ministers, 3
MyABDR portal, 47, 49
N
National Blood Account, 84–85
National Blood Agreement, 3, 84, 88
evaluations undertaken under Schedule 4, 43
functions and objectives under, 45, 50, 63
National Blood and Blood Product Wastage Reduction Strategy 2013–2017, 43, 54
National Blood Authority Act 2003, 3, 12, 45, 84
National Blood Authority Board, 12–14, 71, 154–157
National Blood Research and Development Strategic Priorities 2013–2016, 63, 64
National Blood Sector Data and Information Governance Framework, 44
National Blood Sector Data and Information Strategy and Scorecard 2013–2016, 43–44
National Blood Sector Education and Training Strategy 2013– 2016, 59
National Blood Sector ICT Strategy 2013–16, 46
National Blood Sector Research and Development Pilot, 64–65, 69
National Blood Supply Contingency Plan, 44
National Haemophilia Guidelines, 10, 54
National Haemovigilance Report 2016, 43
National Immunoglobulin Governance Advisory Committee, 41
National Inventory Management Framework, 35
National Managed Fund (Blood and Blood Products) Special Account, 84–85
National Network of Immunoglobulin Governance Committees, 42
National Patient Blood Management Collaborative, 10
National Patient Blood Management Guidelines Implementation Strategy 2013–2017, 54
National Safety and Quality Health Service Standards, 59
National Service Requirements and Standards, 35
National Supply Plan and Budget, 24–33, 87–88
National Supply List inclusions, 33, 43
Neonatal and Paediatric PPM Guidelines Module, 60
neurology, 33, 41, 42
non-English speaking backgrounds, employees from, 77
non-financial assets, 87
non-ongoing staff, 4, 77, 80
normal immunoglobulin (NIg), 33, 163
Northern Territory, 44
Novo Nordisk Pharmaceuticals Pty Ltd, 26, 40, 160
NPS Medicine Wise, 55, 56
O
O negative blood units, 36
Obstetrics and Maternity PBM Guidelines module, 59
occupational health and safety, 81
Octapharma Australia Pty Ltd, 26, 38, 162
Ombudsman, 73
ongoing staff, 4, 77, 80
online services, see information communication technology
operating result, 86–89
Blood Service, 35
operational planning, 70–72
Organ and Tissue Authority, 11
organ transplantation, 41, 42
organisation and structure, 2–14, 68–70
organisation chart, 4
Ortho-Clinical Diagnostics, 26, 40
outcome, 3
Output Based Funding Model (OBFM), 27, 34, 35
overseas horizon scanning, 50–51
P
Parliamentary committees, 73
part-time staff, 77
patient blood management, 52–56, 64
Patient Blood Management (PBM) Guidelines, 10, 54, 55–56, 60
BloodSafe eLearning Australia releases based on, 55, 59
Module 1 pilot to update, 10, 69
performance indicator, 23
payroll contract, 80
people management, 74, 75–81
performance indicators, 20–23
Australian Red Cross Blood Service, 34–35
CSL Australian Fractionation Agreement, 36–37
environmental performance, 166–167
imported intravenous immunoglobulin, 38
imported plasma-derived and recombinant products, 40
performance pay, 80
performance statement, 18–65
Perioperative Patient Management Blood Guidelines, 56
Pfizer Australia Pty Ltd, 26, 40, 161
planning, 14, 70–72
blood supply contingencies, 44
plasma and recombinant products, 24, 25–26, 30–33
supply contracts, 36–40, 160–163
supply risk mitigation, 44, 45
see also immunoglobulins
plasma for fractionation, 27, 29, 36–37, 159
platelets, 29, 159
inventory management, 35, 53
Portfolio Budget Statements performance criteria, 20–23
Preoperative Patient Blood Management Guide, 56
prices, 27, 30, 159–163
procurement, see purchasing
productivity gains, 80
Project Governance Boards, 69
promotion and communication, 57–58
see also information communication technology
Protein C, 39, 162
Public Governance, Performance and Accountability Act 2013, 3, 19
Public Governance, Performance and Accountability Rule 2014, 74
Public Service Act 1999, 3
purchasing, 91–92
advertising and market research, 164
payroll contract, 80
purchasing of blood and blood product supply, 3, 24–28, 84–85, 87–88, 159–163
contract management, 34–40
plasma and recombinant products, 24, 25–26, 30, 33, 36–40, 160–163
savings, 9, 27, 30
see also inventory management
Q
quality improvement initiatives,
see safe and efficient use
Queensland, 44
R
recombinant products, see plasma and recombinant products
red blood cells, 28, 29, 159
diagnostic reagent products, 40
inventory management, 35
supply risk mitigation, 44
wastage (discards), 23, 43
remuneration of staff, 78–79, 80
research and development, 63–65, 69
Blood Service, 35–36
resource statements, 169–170
revenue, see finance
Review of Risk Management in the Blood Sector, 45
risk management, 70
blood sector, 44–45
Ross River Virus, 36
Rural Medicine Australia conference, 58
S
safe and efficient use, 10, 22–23, 52–65
salary and remuneration, 78–79, 80
satisfaction with Blood Service, 35
savings, 9, 27, 30
sector monitoring, 50–51
security of supply, see supply
Senior Executive Management, 68, 69
senior executive service, 79, 80
Seqirus Pty Ltd, 26, 40
Service Charter, 73
small business, procurement initiatives to support, 92
South Australia, 44, 53
special accounts, 84–85
staff, 4, 74, 75–81
stakeholders, 62
engagement program, 13
standards, 44, 59
Blood Service, 35
Strategic Framework for the National Haemovigilance Program, 43
subcutaneous immunoglobulin (SCIg), 33, 162
supply, 9, 20–21, 24–40, 159–163
risk management, 44–45
supply chain management,
see inventory management
surgery, for patients with anaemia, 56
T
Tasmania, 44
tenders, see purchasing
training, see education and training
transfusions, 44, 59
PBM Modules, 10, 60
red cell diagnostic reagent products, 40
transplantation, 41, 42
tribunal decisions, 73
V
values, 76
Victorian Wastage Summit, 61
W
wastage (discards), 23, 61
platelets, 53
reduction strategy, 43, 53
website services,
see information communication technology
Western Australia, 41, 44
whole blood, 29, 35, 159
work health and safety, 8
whole blood, 26, 33, 151
work health and safety, 75, 156